Search clinical trials for: CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg

Total 40 results

Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Healthy Volunteers

United States
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Healthy Volunteers

United States
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.

Healthy Volunteer

China
Woman's
AstraZeneca

Completed

Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women (DAPA-GDM)

Diabetes Prevention in Women After GDM Who Are at High-risk

United States
AstraZeneca

Completed

Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

Type 2 Diabetes Mellitus

United Kingdom
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Healthy

United States
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects

Type II Diabetes
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Unknown

Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients (INHIXACOV19)

COVID-19

Italy
GlaxoSmithKline

Completed

A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib

Neoplasms, Breast

United States, Korea, Republic of
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Healthy

United States
Idorsia Pharmaceuticals Ltd.

Completed

Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)

Healthy
GlaxoSmithKline
Piramal Clinical Research (Hyderabad, India)

Completed

Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of Acetylsalicylic Acid (ASA) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fed Conditions

Ulcers, Duodenal and Gastric

India
GlaxoSmithKline
Piramal Clinical Research (Hyderabad, India)

Completed

Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of ASA (Acetylsalicylic Acid) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fasting Conditions

Ulcers, Duodenal and Gastric

India
Dexa Medica Group

Completed

Bioequivalence Evaluation of Two Film-Coated Formulations of Valsartan 160 mg

Healthy

Indonesia
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg

Healthy

United States
GL Pharm Tech Corporation

Completed

Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers

Healthy

Korea, Republic of
AIO-Studien-gGmbH
Taiho Pharmaceutical Co., Ltd.; Nordic Pharma SAS

Completed

Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer (MATEO)

Esophageal Neoplasms | Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Gastric Neoplasm | Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

Germany
GL Pharm Tech Corporation

Completed

Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers(Fed)

Healthy

Korea, Republic of
GlaxoSmithKline

Completed

Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Tablet Formulations of Amlodipine and Losartan FDC5/50 and FDC5/100 Under Fasting Conditions

Hypertension

South Africa
Supernus Pharmaceuticals, Inc.

Completed

Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

Partial Epilepsy

United States, Poland, Bulgaria, Romania, Canada, Russian Federation, Mexico, Croatia
Kaohsiung Veterans General Hospital.

Completed

Comparing the Efficacy of Reverse Hybrid Therapy and Concomitant Therapy

Helicobacter Pylori Infection

Taiwan
Kaohsiung Veterans General Hospital.

Completed

Comparing the Efficacy of Reverse Hybrid Therapy and Bismuth Quadruple Therapy

Helicobacter Pylori Infection

Taiwan
EMD Serono

Completed

Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction

Anovulation

United States
Merck Sharp & Dohme LLC
Pfizer

Completed

Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)

Diabetes Mellitus, Type 2
Kirby Institute

Active, not recruiting

Body Composition Sub-study of the D2EFT Trial

HIV Infections

Malaysia, Zimbabwe, India, South Africa, Thailand
Royal Marsden NHS Foundation Trust
Hoffmann-La Roche; Professor Cunningham's Clinical Research Fund

Completed

Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer (TARGET)

Pancreatic Cancer

United Kingdom
Kaohsiung Veterans General Hospital.

Unknown

Comparing the Efficacy of 10-day Reverse Hybrid Therapy and 10-day Triple Therapy Plus Bismuth Therapy.

Helicobacter Pylori Infection

Taiwan
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Metastatic Castration-Resistant Prostate Cancer

United States, Austria, Canada, France, Germany, Ireland, Italy, Mexico, Netherlands, New Zealand, Poland, Russian Federation, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, Spain, Finland, Australia, Denmark
Mahidol University

Unknown

Efficacy of Adrenaline in Periarticular Analgesic Injection on Postoperative Pain Control After Total Knee Arthroplasty

Postoperative Pain

Thailand
St Stephens Aids Trust
Merck Sharp & Dohme LLC

Completed

Renal Integrase Study

HIV

United Kingdom
Rabin Medical Center
Tel Aviv University; The Leona M. and Harry B. Helmsley Charitable Trust

Recruiting

Biomarker-based Multidisciplinary Team (Bio-MDT) Approach to Personalized Microbial-targeted Treatment of Pouchitis and Crohn's Disease (Bio-MDT)

Inflammatory Bowel Diseases

Israel
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade... and other conditions

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Withdrawn

SMMART Adaptive Clinical Treatment (ACT) Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent... and other conditions

United States

3

Subscribe